Transgenic mice overexpressing transforming growth factor-β1 (TGF mice) display impaired cerebrovascular reactivity, cerebral hypoperfusion and neurovascular uncoupling, but no overt cognitive deficits until old age. Cardiovascular diseases are a major risk factor for vascular cognitive impairment and dementia (VCID). We investigated the impact of a high cholesterol diet (HCD) on cerebrovascular and cognitive function in adult (6 months) and aged (12 months) TGF mice, together with the potential benefit of simvastatin (SV), an anti-cholesterol drug with pleiotropic effects, in adult mice. HCD increased blood, but not brain, cholesterol levels in treated mice, which SV did not reduce. In WT mice, HCD induced small, albeit significant, impairment in endothelium-dependent dilatory function. In TGF mice, HCD worsened the established brain vessel dilatory dysfunction in an age-dependent manner and increased the number of string vessels in the white matter (WM), alterations respectively normalized and significantly countered by SV. HCD triggered cognitive decline only in TGF mice at both ages, a deficit prevented by SV. Concurrently, HCD upregulated galectin−3 immunoreactivity in WM microglial cells, a response significantly reduced in SV-treated TGF mice. Grey matter astrogliosis and microgliosis were not affected by HCD or SV. In the subventricular zone of adult HCD-treated TGF mice, SV promoted oligogenesis and migration of oligodendrocyte progenitor cells. The results demonstrate that an underlying cerebrovascular pathology increases vulnerability to cognitive failure when combined to another risk factor for dementia, and that WM alterations are associated with this loss of function. The results further indicate that myelin repair mechanisms, as triggered by SV, may bear promise in preventing or delaying cognitive decline related to VCID.

Introduction

Alzheimer’s disease (AD) and vascular cognitive impairment and dementia (VCID), the two most common forms of dementia in the aging population, are both heterogeneous and multifaceted. VCID is characterized as a progressive cognitive decline attributable to cerebrovascular factors. VCID has been associated with increased cerebral blood vessel thickness and stiffness (vascular fibrosis), endothelial dysfunction, and small vessel disease. These impairments result in chronically reduced cerebral perfusion leading to shortage of oxygen and nutrients supply to the brain parenchyma, with a high vulnerability of the white matter (WM) particularly in VCID related to small vessel disease. The traditional risk factors for heart disease and stroke, such as diabetes, hypercholesterolemia, hypertension, obesity, and sedentariness are also the main risk factors for both VCID and AD.

A commonality of VCID and AD is the presence of an inflammatory response, which likely plays a key role in the development and progression of WM lesions and neuronal loss, leading to learning and memory deficits. In this case, the results demonstrate the potential benefits of simvastatin in preventing or delaying cognitive decline related to VCID.
respect, altered levels of the multifunctional cytokine transforming growth factor-β1 (TGF-β1) are found in brain, plasma, cerebrospinal fluid or brain vessels of both AD and VCID patients. Additionally, impaired TGF-β1 signaling was reported in various forms of small vessel diseases, and TGF-β1 polymorphisms have been associated with VCID or with an increased risk for VCID and AD.

Interestingly, transgenic mice that overexpress a constitutively active form of TGF-β1 (TGF mice) in brain display a cerebrovascular pathology that includes vascular fibrosis characterized by accumulation of structural proteins in, and thickening of, the vessel basement membrane, smaller capillary endothelial cells, pericytes, degenerating capillaries and, ultimately, a string vessel pathology characterized by loss on capillary endothelial cells, capillary remnants or intercapillary bridges. These changes are accompanied by impaired cerebrovascular reactivity, chronic cerebral hypoperfusion, and impaired neurovascular coupling. Such alterations recapitulate particularly well those seen in VCID, and, except for the cerebral amyloid angiopathy in AD. Yet, despite impaired cerebrovascular function and increased astroglial TGF-β1 production and secretion that can affect brain homeostasis through signaling alterations in different cellular compartments, TGF mice display no or subtle cognitive deficits even late in age. This raised the possibility that a compromised cerebral circulation may promote cognitive failure when combined with another risk factor for dementia. Therein, we tested this hypothesis in adult and aged TGF mice rendered or not hypercholesterolemic and, in adult mice, we further tested the potential benefits of the anti-cholesterol drug simvastatin (SV) known for its pleiotropic effects on the brain vasculature, neuronal function, and WM.

**Results**

**High cholesterol diet (HCD) increased blood, but not brain, cholesterol levels: effects of simvastatin (SV)**

HCD increased total blood cholesterol levels more than two-fold in adult and aged WT and TGF mice compared to mice fed a normal diet (Supplementary Table 1). In blood, low-density lipoprotein (LDL) cholesterol was low in control WT and TGF mice, but dramatically increased in HCD-treated groups. High-density lipoprotein (HDL) cholesterol slightly increased in HCD-treated mice, and there was no change in the levels of blood triglycerides between any of the groups (Supplementary Table 1). SV did not affect blood total cholesterol levels in WT or TGF mice fed a HCD, and it had negligible or no effects on blood LDL, HDL, and triglycerides (Supplementary Table 1). In brains of adult TGF mice, neither HCD nor SV affected total cholesterol levels (Supplementary Table 2).

HCD induced cognitive deficits selectively in TGF mice: effects of SV

WT and TGF mice were as effective in finding the visible platform (Fig. 1), indicating no visual, motor or motivation deficits. In the hidden platform testing, adult TGF mice performed as well as WT controls, whereas aged TGF mice exhibited slightly, albeit not significant, longer latency time to find the platform (Fig. 1). HCD induced learning deficits in both adult and aged TGF mice. Adult HCD-fed TGF mice differed from the other groups only on the last day of hidden platform testing, whereas aged HCD-fed TGF mice needed more time to find the platform compared to all other groups on most days of testing (Fig. 1). During the probe trial, adult and aged TGF mice performed as well as age-matched control WT mice (Fig. 1). In contrast, HCD-fed TGF mice,
irrespective of age, showed deficits compared to all groups, as shown by a shorter time spent in the target quadrant and less crossings over the previous location of the platform (Fig. 1). Learning and memory performances of adult and aged WT control mice were not affected by HCD. In adult TGF mice, cognitive deficits induced by HCD were prevented by SV, SV HCD-treated mice performing as well as control TGF mice (Fig. 1, right panel).

**Age-dependent impairments of HCD on cerebrovascular function in TGF mice: effects of SV**

TGF mice of both ages displayed impaired dilations to acetylcholine (ACh) and calcitonin gene-related peptide (CGRP) compared to WT controls, CGRP dilations being even reversed to contractile responses. However, there were no significant alterations in their contractile response to endothelin−1 (ET-1) or basal nitric oxide (NO) bioavailability following nitric oxide synthase (NOS) inhibition with Nω-nitro-L-arginine (L-NNA) (Fig. 2, Table 1). HCD had minor effects in adult TGF mice resulting in modest impairments in ET-1-mediated contractions, without worsening the already present dilatory deficits (Fig. 2, Table 1). In contrast, in aged TGF mice, HCD worsened the existing impaired dilatory responses to both ACh and CGRP, and it significantly reduced the contractile response to NOS inhibition, without altering ET-1 contractile responses (Fig. 2, Table 1). In adult and aged WT controls, HCD induced selective impairments in endothelial-mediated ACh dilations (Fig. 3), aged WT mice being more severely affected (Fig. 2, Table 1). None of the deficits were attributed to receptor desensitization since ACh and CGRP pD2 values did not differ between groups (Table 1).

In adult HCD-fed TGF mice, SV improved ACh-mediated and CGRP-mediated dilations (Fig. 2, bottom panel), maximal responses being comparable to those found in similarly aged WT control mice (Fig. 2, top panel, and Table 1). When using the channel opener GSK1016790A to investigate endothelial transient receptor potential vanilloid type 4 (TRPV4) channels that mediate ACh-induced dilations in mouse brain arteries and that are impaired in TGF mice, we found no aggravating effect in HCD-fed TGF mice compared to untreated TGF mice. SV fully restored this deficit in adult HCD-fed TGF mice (Fig. 2, bottom panel) with maximal responses being comparable to those for ACh in similarly aged WT mice (Table 1). ATP-sensitive K+ (KATP) channels mediate a large proportion of CGRP-induced dilations in mouse brain arteries, and dilations induced by the selective KATP channel opener levomakalim were similarly reduced in vessels from adult TGF mice fed or not a HCD (Fig. 2, Table 1). SV significantly improved KATP channel function in vessels from HCD-fed mice (Fig. 2, p < 0.05, Table 1). In a subset of adult TGF mice in which whisker-evoked neurovascular coupling responses were measured, untreated TGF mice displayed the expected impaired CBF increase (7.91 ± 1.13 in TGF vs 14.41 ± 2.21% in WT mice). The latter was not worsened by a HCD (124%, n.s.), but it was significantly improved (144%, p < 0.05) in adult HCD-fed TGF mice treated with SV (6.02 ± 1.03 in HCD-fed TGF mice vs 10.74 ± 1.01 in those treated with SV).

**String vessel pathology in TGF mice: effects of HCD and SV**

String vessels correspond to degenerating capillaries with no endothelial cell layer but only a thin basal membrane that can be immunodetected with collagen IV. HCD significantly increased the number of string vessels in the hippocampus (29.0 ± 4.2 vs 44.3 ± 4.3, p < 0.01), but not cerebral cortex (11.3 ± 2.0 vs 12.7 ± 3.5, ns) of adult TGF mice, having no effect in WT mice that displayed low number of these vessels (n < 10) in both regions. When focusing on the WM, only a few string vessels were found in the corpus callosum (cc) and internal capsule (IC) of WT mice (Fig. 3). This number significantly increased in TGF mice, a pathology exacerbated in the IC of HCD-fed TGF mice (Fig. 3). In adult HCD-fed TGF mice, SV significantly reduced the number of string vessels in both WM areas (Fig. 3), but not in hippocampus (60.0 ± 3.4 in HCD-TGF vs 53.5 ± 3.1 in SV treated HCD-TGF mice).

**HCD selectively affects microglial cells in the WM: effects of SV**

Astroglial and microglial cells in the cortex of TGF mice display a reactive phenotype, which was not improved by SV. Here, we found a similar reactive phenotype in the cc of adult TGF mice compared to WT mice (Fig. 4). Intensity of GFAP immunoreactive material was significantly increased, whereas both staining intensity and surface area of single Iba-1-immunopositive microglial cells were increased in the cc of TGF mice compared to WT controls (Fig. 4a, b). These phenotypes were not aggravated by HCD (Fig. 4a, b) and not reduced by SV treatment (Fig. 4c, d). In contrast to widespread Iba-1-positive microglial cells in grey and WM, we found that galectin-3 (Gal-3), a member of the galectin family of β-galactoside binding lectins found in microglia and macrophages that phagocytose myelin debris, was selectively expressed in microglial cells in the WM (Fig. 5).

Gal-3 immuoreactive cells were rare in the cc and IC of adult WT mice, irrespective of being fed a HCD or not, and were slightly but not significantly more numerous in TGF mice (Fig. 5). In contrast, the number of, surface area occupied by or staining intensity (data not shown, IC only) of Gal-3 positive cells in these WM areas were significantly increased in HCD-fed TGF mice (Fig. 5). SV treatment in adult TGF mice significantly reduced this
upregulating effect of HCD in both the cc (40% in the number of cells) and IC (32% decrease in surface area and staining intensity, respectively) (Fig. 5). Most WM Gal-3 positive cells displayed a microglial phenotype, as confirmed by double-immunofluorescence with Iba-1 (Supplementary Fig. 1). Immunostaining for F4/80, a marker of activated microglia and macrophages, was barely detectable in the cc of WT and TGF mice, but was dramatically increased (~6 fold, \( p < 0.001 \)) in HCD-fed TGF, but not WT, mice; a response blocked by SV (Supplementary Fig. 2).

**SV upregulated oligogenesis and MAP kinase signaling in HCD-fed TGF mice**

Doublecortin (DCX)-positive neuroblasts are found in the subventricular zone (SVZ) of the lateral ventricles.
where they normally migrate along the rostral migratory stream (RMS) to the olfactory bulb to generate interneurons. However, when demyelination occurs, DCX cells alter their properties and migratory path to become new oligodendrocytes. Here, we found a cluster of DCX-immunopositive cells at the RMS-cc border of the SVZ in both WT and TGF mice, with numerous DCX-positive cells in the cc (Fig. 6). Whereas HCD did not alter this pattern, SV dramatically increased DCX-positive cells and, particularly, the density of cells in the cc in HCD-fed TGF, but not in WT mice (Fig. 6). Since progenitor cells expressing PSA-NCAM in the adult SVZ have been identified as a source of remyelinating oligodendrocytes, we studied whether the RMS could be a source of newly generated oligodendrocyte progenitor cells (OPCs) for myelin repair. Our results show a reduced number, albeit not statistically significant, in PSA-NCAM-positive cells at the RMS-cc border of TGF and HCD-fed TGF mice

| Table 1  | (a) Effect of high cholesterol diet (HCD) on cerebrovascular reactivity in adult mice |
|----------|-----------------------------------------------------------------------------------|
|          | WT (3)                          | TGF (4)                          | WT (HCD) (3)            | TGF (HCD) (3)           |
| ACh (Emax) | 50.2 ± 2.03                     | 32.3 ± 1.10***                   | 36.9 ± 1.48***          | 28.8 ± 1.32***          |
| (pD2)     | 7.19 ± 0.13                     | 7.68 ± 0.13*                    | 8.22 ± 0.16**           | 8.54 ± 0.20**           |
| CGRP (Emax) | 50.3 ± 2.25                     | −2.9 ± 4.60***                  | 48.8 ± 1.56             | −1.2 ± 4.54***          |
| (pD2)     | 8.20 ± 0.19                     | 8.99 ± 0.30                     | 7.96 ± 0.14             | 8.9 ± 0.28              |
| ET-1 (Emax) | 44.7 ± 1.6                      | 40.7 ± 2.71                     | 53.9 ± 2.42*            | 34.1 ± 2.74*            |
| (pD2)     | 7.82 ± 0.11                     | 8.06 ± 0.24                     | 7.93 ± 0.15             | 7.21 ± 0.24             |
| L-NNA (Emax) | 37.3 ± 2.09                     | 25.9 ± 1.44**††                 | 34.9 ± 1.76             | 23.3 ± 2.26**††         |

(b) Effect of high cholesterol diet (HCD) on cerebrovascular reactivity in aged mice

|          | WT (3)                          | TGF (3)                          | WT (HCD) (3)            | TGF (HCD) (3)           |
| ACh (Emax) | 60.7 ± 2.24                     | 24.4 ± 1.30***††                 | 40.1 ± 2.51***          | 11.4 ± 1.22***††**      |
| (pD2)     | 7.37 ± 0.13                     | 6.75 ± 0.17                     | 7.67 ± 0.24             | 681 ± 0.33              |
| CGRP (Emax) | 44.5 ± 2.34                     | 1.0 ± 9.37***†††                | 49.4 ± 2.67             | −5.2 ± 6.47***†††       |
| (pD2)     | 7.51 ± 0.19                     | 7.70 ± 0.87                     | 7.73 ± 0.21             | 698 ± 0.23              |
| ET-1 (Emax) | 38.9 ± 2.46                     | 35.0 ± 3.69                     | 46.2 ± 2.32             | 55.3 ± 3.59**           |
| (pD2)     | 8.24 ± 0.18                     | 8.72 ± 0.36                     | 8.11 ± 0.14             | 8.15 ± 0.20             |
| L-NNA (Emax) | 32.4 ± 2.68                     | 37.3 ± 3.19                     | 33.6 ± 2.33             | 12.7 ± 1.43***††***     |

(c) Effect of simvastatin on cerebrovascular reactivity in adult TGF mice treated with HCD

|          | TGF (4)                          | TGF (HCD) (3)                   | TGF(HCD)(SV) (4)        |
| ACh (Emax) | 29.4 ± 1.23                      | 29.5 ± 1.54                     | 42.3 ± 1.48             |
| (pD2)     | 7.21 ± 0.15                      | 7.85 ± 0.22                     | 7.87 ± 0.13             |
| CGRP (Emax) | −2.7 ± 3.35                      | −2.9 ± 2.79                     | 34.9 ± 1.52             |
| (pD2)     | 7.69 ± 0.31                      | 7.26 ± 0.24                     | 8.30 ± 0.19             |
| GSK (Emax) | 298.1 ± 6.44                     | 248.1 ± 1.34                    | 47.6 ± 1.93             |
| (pD2)     | 7.79 ± 0.19                      | 7.97 ± 0.14                     | 7.96 ± 0.19             |
| LEV (Emax) | 20.4 ± 2.16                      | 26.1 ± 1.50                     | 37.1 ± 1.88             |
| (pD2)     | 7.75 ± 0.49                      | 8.04 ± 0.24                     | 8.13 ± 0.24             |

Data are means ± SEM of the number of mice indicated within parentheses, and are expressed as the maximal agonist response (Emax) or potency (pD2: −log EC50 value). Emax is the percentage of maximal dilation to acetylcholine (ACh), calcitonin gene-related peptide (CGRP), that TRPV4 channel opener GSK1016790A (GSK) and the KATP channel opener levcromakalim (LEV) or the maximal percentage decrease in the diameter of arteries to ET or incubated (40 min) with the NOS inhibitor L-NNA (10−5 M). *p < 0.05, **p < 0.01, ***p < 0.001 when compared to WT; ###p < 0.01 when compared to TGF; ††p < 0.01; †††p < 0.001 when compared to WT (HCD); ††††p < 0.01; †††††p < 0.001 when compared to TGF (HCD) by two-way ANOVA (A, B) or one-way ANOVA (C) followed by a Newman-Keuls post-hoc analysis.
compared to WT mice (Fig. 7). SV significantly increased PSA-NCAM immunopositive area in HCD-fed TGF mice, bringing it to levels comparable to WT mice; SV having no effect in WT mice (Fig. 7 left panel). Oligodendrocyte transcription factor 2 (Olig2) can promote differentiation of adult SVZ neuroblasts into functional oligodendrocytes and Olig2 upregulation in OPCs is a possible mechanism in myelin repair. Here, although Olig2 positive cells in the cc were generally reduced in TGF compared WT mice, only HCD-fed TGF mice displayed a statistically significant decrease compared to WT groups, a similar trend being observed in HCD-fed WT mice.
mice (Fig. 7 right panel). Myelin repair having been associated with activation of the MAP kinase/ERK pathway, we then investigated phospho-MAP kinase (pMAPK) immunopositive material in the cc; and it was detected only in HCD-fed TGF mice treated with SV (Supplementary Fig. 3). At the RMS-cc border, pMAPK-positive cells were intermingled but not colocalized with Gal-3 immunostained cells (Supplementary Fig. 3).

Discussion

The most important findings from this study are: (1) HCD in TGF mice age-dependently worsened cerebrovascular dysfunction whereas it triggered cognitive deficits irrespective of age; (2) HCD’s main effect in TGF mouse brain corresponded to an inflammatory response of the WM characterized by upregulation of Gal-3-immunopositive microglial cells; (3) In HCD-fed adult TGF mice, SV treatment reduced WM inflammation, enhanced oligogenesis in the SVZ and migration of OPCs in the cc, and fully rescued both cerebrovascular and cognitive deficits without altering blood cholesterol levels. These results demonstrate that a compromised cerebral circulation, when coupled to a comorbid cardiovascular risk factor as seen in the aging population, can exacerbate cerebrovascular dysfunction, alter WM integrity and lead to cognitive failure. They further indicate that cognitive failure in this model of VCID was selectively associated with WM changes, and that both alterations could be countered by SV.
HCD-induced cerebrovascular alterations and cognitive impairment

The age-related worsening of endothelium-dependent dilatory function and NO bioavailability in cerebral arteries of HCD-fed TGF mice together with the small harmful effect of HCD on endothelial function in WT mice indicated respective exacerbating effects of hypercholesterolemia on TGF mice with an existing compromised brain circulation and deleterious ones in WT mice, with a higher vulnerability of the aged brain vasculature. Brain endothelial cells are sensitive to high levels of circulating cholesterol and, particularly, of LDLs and oxidized LDLs that promote oxidative stress and inflammatory mediator secretion leading to impaired vasoreactivity. Our findings concur with HC levels affecting NO bioavailability and eliciting a pro-inflammatory status in endothelial cells, with...
consequences on NO-dependent cerebrovascular homeostasis, astrocyte differentiation, angiogenesis and neurovascular coupling. HCD could also affect endothelial transport of glucose, the main energy source for supporting neuronal activity. We previously found intact stimulus-induced glucose uptake in TGF mouse brain, but HCD could conceivably alter this astroglial and neuronal uptake.

WM disease contributes to cognitive impairment, and WM alterations detected by MRI in patients with VCID have been attributed to reduced perfusion and/or WM inflammation and/or WM degeneration. We did not measure CBF in the WM, but the increased number of degenerating capillaries (string vessels) in the IC of HCD-fed TGF mice would support exacerbation of an already reduced WM perfusion in TGF mice. Our findings provide arguments for endothelial cell dysfunction and cerebral hypoperfusion being aggravated by HCD, which could lead to WM alterations and, ultimately, cognitive failure. Interestingly, plasma levels of 24-s-hydroxycholesterol (24S-OHC), a brain penetrant metabolite of blood cholesterol, has been associated with cognitive deficits in hypercholesterolemic rodents, and correlated positively with cognitive impairment in patients with VCID. Overall, our findings in TGF mice agree with previous studies whereby HCD altered cognitive function.
only in susceptible mice with either diabetes or an amyloid patholo-
gy. Interestingly, crossing of the same TGF mice with a mouse model of amyotrophic lateral sclerosis (SOD1G93A) accelerated disease progression, an effect counteracted by inhibiting TGF-β1 signaling through TGF-β type I receptors/small mothers against dec-
apetaplegic (Smad) and non-Smad pathways. Moreover, repression of TGF-β1 signaling pathway in astrocytes exerted cognitive benefits in an AD mouse model. Therefore, we conclude that a susceptible brain with a cerebrovascular pathology resulting from increased brain levels of TGF-β1 as seen in TGF mice and patients with VCID may have high relevance to the pathogenesis and progression of cognitive deficits seen in VCID.

**WM alterations and cognitive deficits**

In various models of WM injury, Gal-3 was increased in activated microglial cells that phagocytose myelin debris. Recently, increased density of Gal-3 activated microglial cells in frontal WM areas of aged non-human primates was found to correlate with cognitive impairment. Together, these observations support our most striking finding of selective Gal-3 positive microglial cell upregulation in the WM of cognitively impaired HCD-fed TGF mice. Gal-3 microglial cells are thought to limit WM demyelination by facilitating oligodendrocyte differentiation and, thereafter, remyelination. It is thus tempting to suggest that the selective upregulation of WM Gal-3 microglial cells in HCD-fed TGF mice corresponded to an attempt to repair myelin damage underlying the cognitive decline. Control TGF mice displayed some WM Gal-3 microglial cell pathology that was amplified by HCD concurrently with the advent of cognitive failure, which underscored the damaging effects of HCD when combined to an existing cerebrovascular pathology in an already compromised brain. This also suggests an existing inflammatory state in the WM of TGF mice, too weak to alter cognition, but possibly increasing with age to reach a threshold sufficient to trigger the mild cognitive decline occasionally seen in aged TGF mice. Not all Gal-3 positive cells were Iba-1 positive and F4/80-positive cells, reflecting either microglia or macrophages, were increased dramatically in the WM of HCD-treated TGF mice. Further work is needed to elucidate the potential role of infiltrating macrophages in this inflammatory response.

**WM changes and oligodendrocytes**

In demyelinating conditions, DCX-expressing cells can produce oligodendrocytes in the SVZ that migrate in the cc through the RMS. Yet, successful remyelination requires OPCs to proliferate, migrate to areas of demyelinated axons, and assume a final differentiated state. Here, albeit not significant, PSA-NCAM neuroblasts and Olig2-immunopositive cells were much less numerous in the SVZ in TGF and HCD-fed TGF mice compared to WT mice (Fig. 7), consistent with a lack of PSA-NCAM leading to less SVZ-derived cells differentiating into OPGs and migrating along the RMS, two processes inciden-
tally regulated by Gal-3. These findings indicate that oligogenesis is likely impaired in TGF and HCD-fed TGF mice, although cognitive deficits were only observed in the latter group, likely due—at least partly—to their aggravating endothelial pathology. Indeed, endothelial cells play a key role in OPC generation, migration, and differentiation into oligodendrocytes. Recent findings point to SV being therapeutic against the cerebrovascular inflammatory pathology of TGF mice, but having the added benefit of counteracting the aggravating effects of a HCD likely related to oxidative stress.

A link between age-related cerebrovascular dysregulation, diffuse WM disease and cognitive decline has been proposed. Cerebral endothelium dysfunction and WM lesions typical of VCID are more frequent in hypercholesterolemic patients than in healthy controls, and may even contribute to AD pathogenesis. Here, HCD-induced worsening of the cerebrovascular pathology and WM inflammation in TGF mice occurred together with the onset of cognitive deficits, all prevented by SV. Hence, SV immunomodulatory, anti-inflammatory, and anti-
oxidant benefits on the brain vasculature and par-
enchyma likely contributed to counter the cognitive deficits induced by HCD in TGF mice. These benefits occurred without lowering blood cholesterol, consistent with statin effects on lipid oxidation underlying their
protective effects in patients with dislipidemia. As in our study in aged TGF mice without cognitive deficit, SV had no effect on grey matter astrogliosis and microgliosis of cognitively impaired HCD-fed TGF mice, pointing to WM alteration and recovery underlying cognitive failure and rescue.

Therefore, SV silenced the HCD-induced upregulation of Gal-3 in WM microglial cells, raising the possibility that SV can initiate myelin repair leading to cognitive recovery. In the cuprizone model of demyelination, spatial working memory was reestablished after remyelination had occurred. In a mouse model of diffuse WM injury, enhanced generation of OPCs resulted in functional recovery. The increased number of Olig2 cells in the cc of SV-treated mice is compatible with SV promoting oligodendrocyte differentiation, SVZ-derived DCX-positive OPCs contributing to myelin repair, and SV-mediated PSA-NCAM upregulation that is needed for efficient OPCs recruitment to demyelinated areas.

**SV and signaling pathways in WM**

Our findings of elevated pMAPK expression in the RMS of the SVZ in HCD-fed TGF mice concurrently treated with SV support a role for MAPK/ERK signaling in oligodendrocyte proliferation, migration, and maturation and, hence, remyelination. Sustained activation of ERK1/2 was found sufficient to drive adult oligodendrogenesis, contribute to remyelination and enhance hippocampal-based behavior. Other studies indicated that ERK signaling can reactivate quiescent mature oligodendrocytes to reinitiate myelination. Our findings with SV thus support a role for MAPK/ERK pathway in myelin repair and, possibly, cognitive recovery. Cross-talk with other pathways, like the Wnt/β-catenin and Akt/mTOR pathways, however, seems likely.

**Conclusions**

Our findings highlight the relationship between HCD-induced endothelial dysfunction, WM inflammation characterized by Gal-3 upregulation in microglial cells, and cognitive failure. They further demonstrate cerebrovascular, microglial, and WM protective benefits of SV in this model of VCID, with recovery of cognitive function. In the face of an increasingly growing incidence of dementia, VCID being a main contributor, we conclude that targeting WM inflammation and, specifically, Gal-3 microglial cells, may represent a promising therapeutic avenue, as proposed in other models of demyelination accompanied with cognitive deficits.

**Materials and methods**

**Animal model and treatments**

Low expresser heterozygous transgenic mice overexpressing a constitutively active form of TGF-β1 under the control of the glial fibrillary acidic protein (GFAP) promoter on a C57BL/6J background (TGF mice, line T64) were used in this study, with age-matched wild-type (WT) littermate controls. In TGF mice, TGF-β1 mRNA or protein levels are about 2–4 folds higher than in wild-type controls, do not increase with age, and compare well to those found in pathological brains, including AD. Transgene expression was confirmed with touchdown PCR using tail-extracted DNA. Groups of approximately equal number of males and females were used as adult (endpoint 6 months, 11–14 mice/per group) or aged (endpoint 12 months, 11–12 mice/per group) mice, and were randomized between the two treatment groups (standard or HCD). Mice were fed (3 months) either a standard diet (control) diet (4% fat, 14% protein rodent maintenance diet, Harlan Teklad global) or a HCD (supplemented with 2% cholesterol and 0.5% cholic acid, Harlan, TD. 110321). Other cohorts of adult WT and TGF mice (12–14 mice/group) received a HCD alone or concurrently with the cholesterol lowering drug simvastatin (SV, 3 months, Enzo, life science, Farmingdale, USA). SV was activated as per manufacturer’s protocol and added to the drinking water at a concentration of 0.04%, corresponding to ~40 mg/kg body weight/day. All experiments were approved by the Animal Ethics Committee of the Montreal Neurological Institute and complied with the Canadian Council on Animal Care.

**Blood cholesterol levels**

Blood samples were extracted from the heart (4–5 mice/group) in deeply anesthetized mice with isoflurane, just before they were perfused (see below). Blood was collected in Eppendorf tubes, kept at room temperature (2 h), centrifuged (15,000 rpm, 10 min) and supernatants stored (−20 °C) until use. Total cholesterol (TC), LDL and HDL cholesterol, and triglycerides were measured using a blood analyzer (Blood Research Laboratory, Royal Victoria Hospital, McGill University Health Center (MUHC), Montréal, QC, Canada).

**Morris water maze**

Spatial memory was tested in the Morris water maze (MWM), as described before. Mice first received a 3-day habituation period requiring them to swim (1.4 m diameter pool, 17 ± 1 °C opaque water) to a visible platform (60 s trials). The wall cues and platform location were then switched, the platform submerged (1 cm) and mice were submitted to 5 days of hidden-platform testing (three trials from different orientations per day, max 90 s/ trial, 45 min inter-trial interval) during which mice had to find the location of the platform using distal visuo-spatial cues. On day 9, mice were given a probe trial (60 s) in which the percentage of time spent and distance traveled...
in the target quadrant (where the platform used to be located) were recorded, along with swim speed and the number of crossings above the previous platform location. All parameters were recorded and analyzed using 2020 Plus tracking system and Water 2020 software (HVS Image, Buckingham, UK).

**Cerebrovascular reactivity**

Segments (~2 mm long) of the posterior cerebral artery (PCA, 3–5 mice/group) were cannulated, pressurized (60 mmHg) and superfused with a Krebs’ solution in a chamber for on-line videomicroscopy, as described before\(^1,25,22\). Dilutions to ACh (10\(^{-11}\)–10\(^{-4}\) M) and CGRP (10\(^{-11}\)–10\(^{-3}\) M) were tested on vessels pre-constricted sub-maximally with phenylephrine (PE, 2 × 10\(^{-7}\)M). Contraction to ET-1 (10\(^{-11}\)–10\(^{-5}\) M) and the tonic production of the vasodilator NO were measured in vessels at basal tone, the latter after inhibition of NOS with production of the vasodilator NO were measured in vessels. For single immunofluorescent staining, free-floating freezing sections were incubated overnight with either goat anti-collagen IV (Millipore, Billerica, USA, catalog # AB769, 1:300, for staining brain vessels) or antidualbocortin (DCX- (C-18), Santa Cruz, catalog # sc-8066, 1:1000, a marker of migrating neuroblasts), rabbit anti-GFAP (Dako Canada, Burlington, Code-Nr. Z 0334, 1:2000, a marker of astrocytes), anti-phospho MAP kinase (Erk 1/2, Cell signaling, catalog # 9101, 1:100), or anti-oligodendrocyte transcription factor 2 (Olig2, Millipore, catalog # AB9610, 1:1000, a marker of oligodendrocytes), rat anti-galectin-3 (Gal-3) (Mac-2, Cedarlane, catalog # MAB5324, 1:300, for staining brain vessels) or anti-F4/80 (BioCL8942AP, Burlington, ON, Canada, 1:1500, a marker for active WM-related microglial cells) or anti-F4/80 (BioRad, catalog # MCA497, Mississauga, ON, Canada, 1:100, a marker for active microglia or macrophages), or mouse anti-polyasialic acid-neuronal cell adhesion molecule (PSA-NCAM, Millipore, catalog # MAB5324, 1:800, protein that helps migration of oligodendrocyte precursor cells (OPC)) followed by incubation with the corresponding cyanin 2 (Cy2, green)-, Alexa 488 (green)-, cyanin 3 (Cy3, red)- or Alexa 594 (red)-conjugated secondary antibodies (Jackson laboratory, West Grove, PA, USA). For double-immunofluorescence, sections were concurrently incubated overnight with either rat anti-Gal-3 (1:1500) and rabbit anti-Iba-1 (1:300) or anti-phospho MAP kinase, followed by concurrent anti-rabbit Alexa 594 and anti-rat Alexa 488 incubation (Jackson laboratory).

**Data analysis**

Vascular responses (% change diameter from basal or pre-constricted tone) were plotted as a function of agonist concentration or duration of NOS inhibition. Concentration-dependent and maximal (E\text{Amax}) responses and the agonist concentration eliciting half the E\text{Amax} (EC\text{50} value or pD2 = −log EC\text{50}, determined with GraphPad Prism 6) were used to compare agonist efficacy and potency, respectively. String vessels were counted in

---

**Immunohistochemistry and immunofluorescence**

Mice (4–6/group) deeply anesthetized with either pentobarbital (65 mg/kg) or isoflurane (mice used blood sampling) were perfused intracardially with 4% paraformaldehyde (PFA), and their brains post-fixed overnight. Then, half brains were transferred to 30% sucrose for cryoprotection, frozen (−40°C, isopentane) and stored (−80°C until sectioning as free-floating sections (25 μm-thick). The other halves were processed for paraffin embedding and sectioning (5 μm-thick). For immunohistochemical staining of microglial cells, paraffin sections were incubated overnight in rabbit anti-Iba-1 (ionized calcium binding adaptor molecule-1, Wako USA, catalog # 019–19741, Richmond, 1:300), followed by biotinylated IgG (Vector lab, 1 h 30 min), ABC kit (Vector lab, 1 h 15 min), and the reaction visualized with a 0.05% DAB-Nickel solution. For single immunofluorescent staining, free-floating freezing sections were incubated overnight with either goat anti-collagen IV (Millipore, Billerica, USA, catalog # AB769, 1:300, for staining brain vessels) or anti-dark of the right whiskers (20 s, 8 Hz). Four to six recordings were acquired every 30–40 s and averaged for each mouse. The entire procedure lasted less than 20 min, a time window when all physiological parameters remain stable. Cortical CBF changes (peak value) were expressed as percentage increase relative to pre-stimulation baseline level.

**Total brain cholesterol levels**

Measurements of brain total cholesterol levels (3–4 mice/group) were performed with the Cholesterol/Cholesteryl Ester Quantitation kit (ab65359, Abcam, Toronto, ON) according to the manufacturer. Brain tissue was homogenized in a chloroform/isopropanol:Triton x-100 solution (proportion 7:11:0.1), centrifuged (15,000 × g), and the resulting supernatant was dried at 50°C to remove chloroform using speed vacuum concentration (30 min). The sample was diluted, incubated with enzyme reagents (37°C, 60 min), and absorbance was measured (570 nm) in a microplate reader.
the corpus callosum (cc) and internal capsule (IC) directly under the microscope by one (cc) or two independent observers (IC) blinded to the mouse identity. GFAP, Gal-3, and Olig2-positive area in the cc and IC were manually delineated on low-power digital images and measured using MetaMorph (6.1r3 software, Universal Imaging, Downingtown, PA) or Image J (NIH Bethesda, MD, USA). For microglial cells in the cc, 10–12 Iba-1 immunopositive single cells per mouse (4–6 mice/group) and their processes visualized in thin paraffin sections were selected randomly and their surface area measured on low-power images using MetaMorph or Image J. All data are expressed as mean ± SEM and were analyzed by two-way ANOVA (genotype and treatment as the two factors) followed by Newman-Keuls post hoc multiple comparison test or when indicated, by one-way ANOVA or when indicated, by one-way ANOVA for TGF mice with different treatment comparisons (GraphPad Prism6). A p < 0.05 was considered significant.

Acknowledgements

This work was supported by grants (to E.H.) from the Canadian Institutes of Health Research (CIHR MOP-126001), the Alzheimer Society of Canada and the Canadian Vascular Network, and by studenthips awards (to L.T.) from les Fonds de recherche du Québec – Santé (FRQS) and Healthy Brains for Healthy Lives (HBHL) training Program, McGill University. We thank Dr. Lennart Mucke, from the Gladstone Institute of Neurological Disease and Department of Neurology, UCSF, CA, for the TGF mouse breeders. We would also like to thank Dr. Maria Lacalle-Auriolos for providing feedback on the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at (https://doi.org/10.1038/s41419-018-1199-0).

Received: 10 August 2018 Revised: 19 October 2018 Accepted: 25 October 2018

Published online: 28 January 2019

References

1. Iadecola, C. The pathobiology of vascular dementia. Neuron 80, 844–866 (2013).
2. Gorelick, P. B., Counts, S. E. & Nygrenhuis, D. Vascular cognitive impairment and dementia. Biochem. Biophys. Acta 1862, 860–868 (2016).
3. Khan, A., Kalaria, R. N., Corbett, A. & Ballard, C. Update on Vascular Dementia. J. Geriatr. Psychiatry Neurol. 29, 281–301 (2016).
4. Saji, N., Toba, K. & Sakurai, T. Cerebral small vessel disease and arterial stiffness: Tsunami effect in the brain? Neuron 86, 954–962 (2008).
5. Tsao, C.-W. et al. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology 86, 619–626 (2016).
6. Grammas, P. & Ovase, R. Cerebrovascular transforming growth factor-β contributes to inflammation in the Alzheimer’s disease brain. Am. J. Pathol. 160, 1983–1997 (2002).
7. Malaguarnera, M., Motta, M., Di Rosa, M., Anzaldi, M. & Malaguarnera, M. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer’s disease and vascular dementia. Neuropathol. 26, 307–312 (2006).
8. Tarkowski, E. et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia. Neurobiol. Aging 23, 237–243 (2002).
9. Fukutake, T. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leuкоencephalopathy (CARASIL): from discovery to gene identification. J. Stroke Cerebrovasc. Dis. 20, 85–93 (2011).
10. Yamamoto, Y. & Ihara, M. Disruption of transforming growth factor-beta superfamily signaling: A shared mechanism underlying hereditary cerebral small vessel disease. Neurochem. Int. 107, 211–218 (2017).
11. Sur, J. H. et al. Genetics of vascular dementia: systematic review and meta-analysis. J. Alzheimers Dis. 46, 161–209 (2015).
12. Peila, R. et al. TGF-beta1 polymorphism association with dementia and neuropathologies: the HAAS Neurobiol. Aging 28, 1376–1379 (2007).
13. Caracci, F. et al. The CC genotype of transforming growth factor-beta1 increases the risk of late-onset Alzheimer’s disease and is associated with AD-related depression. Eur. Neuropsychopharmacol. 22, 281–289 (2012).
14. Wyss-Coray, T., Lin, C., Sanan, D. A., Mucke, L. & Masliah, E. Chronic over-production of transforming growth factor-β1 by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Ann. J. Pathol. 156, 139–150 (2000).
15. Tong, X. K. & Hamel, E. Simvastatin restored vascular reactivity, endothelial function and reduced string vessel pathology in a mouse model of cerebrovascular disease. J. Cereb. Blood Flow Metab. 33, 512–520 (2015).
16. Nicolakakis, N. et al. Intact memory in TGF-beta1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone. J. Cereb. Blood Flow Metab. 31, 200–211 (2011).
17. Brown, W. R. A review of string vessels or collapsed, empty basement membrane tubes. J. Alzheimers Dis. 21, 725–739 (2010).
18. Gaertner, R. F. et al. Reduced brain tissue perfusion in TGF-beta1 transgenic mice showing Alzheimer’s disease-like cerebrovascular abnormalities. Neurobiol. Dis. 39, 38–46 (2010).
19. Lacombe, P. et al. Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised. J. Neuroinflamm. 11, 1–11 (2014).
20. Lifshitz, V. et al. Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model. Neurobiol. Aging 33, 432e1–413 (2012).
21. Martinez-Canabal, A. et al. Chronic over-expression of TGFbeta1 alters hippocampal structure and causes learning defects. Hippocampus 23, 1196–1211 (2013).
22. Tong, X. K., Lecru, C. & Hamel, E. Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory defects. J. Neurosci. 32, 4705–4715 (2012).
23. B’Desouki, A. M., Galal, M. A., Awad, A. S. & Zaki, H. F. Neuroprotective Effects of Simvastatin and Cistoztazol in L-Methionine-Induced Vascular Dementia in Rats. Mol. Neurobiol. 54, 5074–5084 (2017).
24. Sim, J. F. et al. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. Glia 56, 954–962 (2008).
25. Zhang, L., Papadopoulos, P. & Hamel, E. Endothelial TRPV4 channel mediates dilation of cerebral arteries: impairment and recovery in cerebrovascular pathologies related to Alzheimer’s disease. Br. J. Pharmacol. 170, 661–670 (2013).
26. Rotshenker, S. The role of Galectin-3/MAC-2 in the activation of the innate immune function of phagocytes in microglia in injury and disease. J. Mol. Neurosci. 39, 99–103 (2009).
27. Kettenmann, H., Hanisch, U. K., Noda, M. & Verkhovsky, A. Physiology of microglia. Physiol. Rev. 91, 461–553 (2011).
28. Jabłońska, B. et al. Chordin-induced lineage plasticity of adult SVZ neuroblasts after demyelination. Nat. Neurosci. 13, 541–550 (2010).
29. Nait-Oumesmar, B. et al. Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination. Eur. J. Neurosci. 11, 4357–4366 (1999).
30. Adams, T. L. & Verdi, J. M. Olig1 and Olig2 promote oligodendrocyte differentiation of neural stem cells in adult mice injured by EAE. Adv. Biosci. Bio technol. 3, 567–573 (2012).
31. Wegener, A. et al. Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination. Brain 138(Pt 1), 120–135 (2015).
32. Iishi, A., Furusho, M., Dupree, J. L. & Bansal, R. Strength of ERK1/2 MAPK Activation determines its effect on myelin and axonal integrity in the adult CNS. J. Neurosci. 36, 6471–6487 (2016).
33. Dias, H. K., Brown, C. L., Poldort, M. C., Lip, G. Y. & Griffiths, H. R. LDL-lipids from patients with hypercholesterolaemia and Alzheimer’s disease are
inflammatory to microvascular endothelial cells: mitigation by statin intervention. Clin. Sci. 129, 1195–1206 (2015).

34. Miller, A. A. et al. Augmented superoxide production by Nox2-containing NADPH oxidase causes cerebral artery dysfunction during hypercholesterolemia. Stroke 41, 784–789 (2010).

35. Shi, Q., Hornsby, P. J., Meng, Q., Vandeberg, J. F. & Vandeberg, J. L. Longitudinal analysis of short-term high-fat diet on endothelial senescence in baboons. Am. J. Cardiovasc. Dis. 3, 107–119 (2013).

36. Mi, H., Haeberle, H. & Barnes, B. A. Induction of astrocyte differentiation by endothelial cells. J. Neurosci. 21, 1538–1547 (2001).

37. Toth, P., Tarantini, S., Csiszar, A. & Ungvari, Z. Functional vascular contributions to cognitive impairment and dementia mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. Am. J. Physiol. Heart Circ. Physiol. 312, H1–H20 (2017).

38. Zimmer, E. R. et al. [18F]FDG PET signal is driven by astroglial glutamate and pathological conditions.

39. Franco-Pons, N., Torrente, M., Colomina, M. T. & Vilella, E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol. Lett. 169, 205–213 (2007).

40. Scafidi, J. et al. Intranasal epidermal growth factor treatment rescues neonatal brain injury. Nature 506, 230–234 (2014).

41. Xie, W. & Du, L. High-cholesterol diets impair short-term retention of memory in alloxan-induced diabetic mice, but not acquisition of memory nor retention of memory in prediabetic mice. Life Sci. 77, 481–495 (2005).

42. Xie, C., Li, Z., Zhang, G. X. & Guan, Y. Wnt signaling in remyelination in multiple sclerosis: friend or foe? Mol. Neurobiol. 49, 1117–1125 (2014).

43. Wyss-Coray, T. et al. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am. J. Pathol. 147, 53–67 (1995).

44. Wyss-Coray, T., Borrow, P., Brooker, M. J. & Mucke, L. Astroglial overproduction of TGF-β1 enhances inflammatory central nervous system disease in transgenic mice. J. Neurommunol. 77, 45–50 (1997).

45. Tong, X. K., Nicolakakis, N., Kocharian, A. & Hamel, E. Vascular remodeling versus amyloid β-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer’s disease. J. Neurosci. 25, 11165–11174 (2005).